Barclays
VMD icon

Barclays’s Viemed Healthcare VMD Stock Holding History

Barclays’s Portfolio VMD Stock Details VMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$710K Sell
62,287
-9,990
-14% -$98.9K ﹤0.01% 2999
2026
Q1 		$666K Sell
72,277
-59,482
-45% -$495K ﹤0.01% 3005
2025
Q4 		$979K Buy
131,759
+3,480
+3% +$23.8K ﹤0.01% 3440
2025
Q3 		$871K Sell
128,279
-15,777
-11% -$107K ﹤0.01% 3451
2025
Q2 		$995K Buy
144,056
+95,726
+198% +$650K ﹤0.01% 3340
2025
Q1 		$352K Sell
48,330
-10,305
-18% -$80.9K ﹤0.01% 3734
2024
Q4 		$470K Buy
58,635
+5,196
+10% +$45.1K ﹤0.01% 3862
2024
Q3 		$392K Buy
53,439
+41,358
+342% +$295K ﹤0.01% 3923
2024
Q2 		$79.1K Sell
12,081
-12,172
-50% -$91.7K ﹤0.01% 4021
2024
Q1 		$229K Sell
24,253
-23,113
-49% -$198K ﹤0.01% 4052
2023
Q4 		$372K Buy
47,366
+40,930
+636% +$297K ﹤0.01% 4057
2023
Q3 		$43.3K Sell
6,436
-1,170
-15% -$9.59K ﹤0.01% 3931
2023
Q2 		$74.4K Sell
7,606
-7,790
-51% -$79.1K ﹤0.01% 3679
2023
Q1 		$149K Buy
15,396
+495
+3% +$4.32K ﹤0.01% 3962
2022
Q4 		$113K Buy
14,901
+13,117
+735% +$88.8K ﹤0.01% 4157
2022
Q3 		$11K Buy
+1,784
New +$11.5K ﹤0.01% 4280
2022
Q2 		– Sell
-5,749
Closed -$29K – 5284
2022
Q1 		$29K Sell
5,749
-37,225
-87% -$173K ﹤0.01% 4317
2021
Q4 		$225K Buy
42,974
+28,504
+197% +$159K ﹤0.01% 3521
2021
Q3 		$80K Buy
14,470
+9,991
+223% +$65K ﹤0.01% 3985
2021
Q2 		$32K Sell
4,479
-24,704
-85% -$214K ﹤0.01% 4343
2021
Q1 		$295K Buy
29,183
+4,752
+19% +$44.7K ﹤0.01% 3508
2020
Q4 		$190K Sell
24,431
-27,033
-53% -$238K ﹤0.01% 3787
2020
Q3 		$446K Buy
51,464
+32,570
+172% +$329K ﹤0.01% 3315
2020
Q2 		$181K Buy
+18,894
New +$147K ﹤0.01% 4140

Other funds holding VMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Forager Capital Management Birmingham, Alabama $266M AUM 40% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Barclays's VMD Position: Q2 2026 in Review

Barclays reduced its Viemed Healthcare (VMD) stake by 14% in Q2 2026, selling an estimated $98.9K and leaving 62,287 shares worth $710K. The position accounts for ﹤0.01% of the portfolio, ranked #2999.

Barclays first reported a position in VMD in Q2 2020 and has held it in 24 quarters since. The position peaked at $995K in Q2 2025. 166 funds tracked by Wall St. Rank hold VMD as of Q2 2026.

  • Barclays held 62,287 shares of Viemed Healthcare worth $710K as of Q2 2026.
  • Barclays sold 9,990 Viemed Healthcare shares in Q2 2026, an estimated $98.9K.
  • Viemed Healthcare made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2999 holding.
  • Barclays first reported a position in Viemed Healthcare in Q2 2020 and has held it in 24 quarters since.
  • Barclays's Viemed Healthcare position peaked at $995K in Q2 2025.
  • 166 funds tracked by Wall St. Rank held Viemed Healthcare as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.